FUSION PHARMACEUTICALS INC's ticker is FUSN and the CUSIP is 36118A100. A total of 41 filers reported holding FUSION PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $855,057 | -44.3% | 328,868 | 0.0% | 0.00% | -60.0% |
| Q2 2023 | $1,535,814 | +23.9% | 328,868 | 0.0% | 0.01% | +25.0% |
| Q1 2023 | $1,239,832 | +19.7% | 328,868 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $1,035,934 | +11.0% | 328,868 | +6.1% | 0.00% | 0.0% |
| Q3 2022 | $933,000 | +13.9% | 310,068 | -5.7% | 0.00% | +33.3% |
| Q2 2022 | $819,000 | -69.9% | 328,868 | -6.0% | 0.00% | -72.7% |
| Q1 2022 | $2,720,000 | -37.8% | 350,000 | -66.6% | 0.01% | -35.3% |
| Q4 2021 | $4,374,000 | -35.6% | 1,048,956 | +22.3% | 0.02% | -43.3% |
| Q3 2021 | $6,795,000 | -3.9% | 858,012 | -2.0% | 0.03% | -6.2% |
| Q2 2021 | $7,071,000 | -12.1% | 875,141 | +16.7% | 0.03% | -15.8% |
| Q1 2021 | $8,040,000 | +24.4% | 750,000 | +36.4% | 0.04% | +18.8% |
| Q4 2020 | $6,463,000 | +516.7% | 550,000 | +816.7% | 0.03% | +357.1% |
| Q2 2020 | $1,048,000 | – | 60,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,670,516 | $11,562 | 3.36% |
| ADAMS STREET PARTNERS LLC | 2,947,809 | $9,285,598 | 3.10% |
| Pivotal bioVenture Partners Investment Advisor LLC | 1,560,984 | $4,917,100 | 2.14% |
| Sio Capital Management, LLC | 260,448 | $820,411 | 0.30% |
| BRAIDWELL LP | 2,000,000 | $6,300,000 | 0.21% |
| Orbimed Advisors | 3,224,770 | $10,158,026 | 0.19% |
| TPG GP A, LLC | 2,551,794 | $8,038,151 | 0.16% |
| Artal Group S.A. | 750,000 | $2,363 | 0.13% |
| RA Capital Management | 659,992 | $2,078,975 | 0.04% |
| SECTORAL ASSET MANAGEMENT INC | 57,297 | $180,486 | 0.04% |